Your browser of choice has not been tested for use with Barchart.com. If you have issues, please download one of the browsers listed here.
or
Menu

Inovio Pharma (INO)

[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (BATS)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
Latest Headlines for [[ item.sessionDateDisplayLong ]]
Why Is Inovio (INO) Up 6.6% Since Its Last Earnings Report?

Inovio (INO) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.

INO : 4.46 (-2.19%)
Inovio Awarded up to $56 Million from CEPI to Advance DNA Vaccines Against Lassa Fever and MERS

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) and CEPI - the Coalition for Epidemic Preparedness Innovations - today announced a partnership under which Inovio will develop vaccine candidates against Lassa...

INO : 4.46 (-2.19%)
Inovio Pharmaceuticals to Present at the H.C. Wainwright Annual Global Life Sciences Conference

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. J. Joseph Kim, Inovio's President & CEO, will provide a corporate overview at the H.C. Wainwright Annual Global Life Sciences Conference,...

INO : 4.46 (-2.19%)
Inovio Closes License and Collaboration Agreement with ApolloBio To Develop and Commercialize VGX-3100 in Greater China

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced it has closed an agreement providing ApolloBio Corp. (NEEQ:430187) with the exclusive right to develop, manufacture and commercialize VGX-3100,...

INO : 4.46 (-2.19%)
Inovio's (INO) Q4 Loss Narrower than Expected, Revenues Beat

Inovio (INO) reports a narrower-than-expected loss in Q4. Moreover, revenues also beat estimates during the period and increased year over year.

AZN : 35.29 (+0.48%)
INO : 4.46 (-2.19%)
RHHBY : 27.8300 (-0.32%)
REGN : 316.17 (+1.34%)
Inovio Pharmaceuticals Reports 2017 Fourth Quarter and Year End Financial Results

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today reported financial results for the fourth quarter and year ended December 31, 2017.

INO : 4.46 (-2.19%)
Inovio's DNA Immunotherapy Demonstrates Immune Response Results Key in Treating Chronic Hepatitis B Infection

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that interim Phase 1 results show its DNA immunotherapy designed to treat hepatitis B virus (HBV) infection was safe, well-tolerated and generated...

INO : 4.46 (-2.19%)
Inovio Pharmaceuticals to Report Fourth Quarter and Year End 2017 Financial Results on March 14, 2018

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today that it will host a conference call and live webcast to report its 2017 fourth quarter and year end financial results on Wednesday, March 14, 2018...

INO : 4.46 (-2.19%)
What's in the Cards for Inovio (INO) This Earnings Season?

Inovio's (INO) most advanced pipeline candidate, VGX-3100's consistent progress might drive the stock in Q4. However, lack of an approved product in the company's portfolio is a dampener.

GEMP : 5.75 (+2.13%)
BDSI : 2.10 (unch)
INO : 4.46 (-2.19%)
REGN : 316.17 (+1.34%)
Market Trends Toward New Normal in Rockwell Collins, Sprouts Farmers Market, Inovio Pharmaceuticals, CVS Health, FirstEnergy, and Welbilt, Inc. -- Emerging Consolidated Expectations, Analyst Ratings

In new independent research reports released early this morning, Fundamental Markets released its latest key findings for all current investors, traders, and shareholders of Rockwell Collins, Inc. (NYSE:COL),...

COL : 133.30 (+0.20%)
CVS : 67.73 (+1.70%)
WBT : 19.03 (+0.85%)
SFM : 24.55 (+0.45%)
INO : 4.46 (-2.19%)
FE : 34.16 (-0.38%)
Inovio and The Wistar Institute Receive More Than $4.6 Million in R&D Funding to Advance Vaccines Against Tuberculosis & Malaria

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the company is collaborating with The Wistar Institute to advance two novel SynCon vaccine programs against tuberculosis (TB) and malaria,...

INO : 4.46 (-2.19%)
Inovio Pharmaceuticals to Participate in Upcoming Investment Conferences

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that the Company will participate in the following upcoming investment conferences:

INO : 4.46 (-2.19%)
Inovio's Influenza Vaccine Shows Potential, Shares Rally

Inovio Pharmaceuticals' (INO) universal influenza vaccine leads to broad protective antibody responses against all major deadly strains of H1 virus.

EBS : 52.28 (-4.11%)
INO : 4.46 (-2.19%)
BVXV : 6.39 (-1.54%)
GSK : 39.12 (-3.74%)
Today's Research Reports on Stocks to Watch: Inovio Pharmaceuticals and CytRx Corporation

NEW YORK , NY / ACCESSWIRE / January 24, 2018 / Inovio was one of the best performing stocks in the market yesterday after the company revealed published data that was encouraging regarding its goal of...

INO : 4.46 (-2.19%)
CYTR : 1.64 (+1.23%)
3 Stocks Under $10 That Surged Today

Here at Zacks, we encourage investors to follow our proven stock-picking system, which places a great deal of emphasis on the importance of earnings estimate revisions in order to identify winning stocks....

RUN : 8.99 (+1.24%)
INO : 4.46 (-2.19%)
NK : 3.99 (-2.21%)
Inovio Pharmaceuticals' Published Universal Flu Vaccine Data Demonstrates Protective Responses Against All Major, Lethal H1N1 Influenza Viruses From the Last 100 Years in Animal Models

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Inovio's synthetic vaccine approach using a collection of synthetic DNA antigens generated broad protective antibody responses against all...

INO : 4.46 (-2.19%)
Inovio's Co-Founder along with its Lead Antigen Designer Named Among Top 20 Researchers With Most Granted U.S Patents for 2016

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) today announced that Dr. David B. Weiner, its co-founder; and Dr. Jian Yan, the company's Lead Antigen Designer, have been selected as two of the "Top 20 Translational...

INO : 4.46 (-2.19%)
Inovio Pharmaceuticals and the Parker Institute for Cancer Immunotherapy Establish Clinical Development Collaboration To Evaluate Novel Cancer Immunotherapy Combinations

-- Advances development of Inovio's ASPIRE(TM) (Antigen SPecific Immune REsponses) immunotherapy platform as a foundation for novel combination regimen approaches

INO : 4.46 (-2.19%)
Inovio Receives Milestone Payment from MedImmune as MEDI0457 and Checkpoint Inhibitor Combination Trial in Head and Neck Squamous Cell Cancer Advances to Phase 2

Inovio Pharmaceuticals, Inc. (NASDAQ:INO) announced today it has received a milestone payment from MedImmune as MEDI0457 (formerly called INO-3112 which MedImmune in-licensed from Inovio) in combination...

INO : 4.46 (-2.19%)
Cancer Space Update: New Regulatory Status for 3 Major Drugs

Merck's Keytruda receives approval in Japan for bladder cancer. Seattle Genetics' Adcetris and Novartis' Kisqali get regulatory status updates from the FDA.

MRK : 59.63 (-0.77%)
NVS : 76.42 (-0.74%)
EXEL : 20.83 (+2.11%)
SGEN : 48.13 (-1.33%)
INO : 4.46 (-2.19%)
CLSN : 2.19 (-1.79%)
RHHBY : 27.8300 (-0.32%)

Van Meerten Stock Picks

5 Great Mid Caps
This morning I wanted to find the Mid Cap stocks that not only had some of the best returns in the past 12 months but still seemed to have some upside potential.
IBKR -0.76 , HFC -0.76 , ABMD +2.27 , CAR +0.46 , URBN +0.92
Jim Van Meerten uses Barchart's tools to offer daily stock picks and recommendations. His portfolios have been honored by Marketocracy and Morningstar.
Free Commodities Newsletter

Get prepared for your trading day with

Barchart's Commodity Futures Morning Update Email

InsideFutures Commentary

InsideFutures weekly newsletter features a selection of the latest and best commodities commentary appearing on Barchart.com. Delivered every Friday morning to your inbox.

Brugler Ag Report

Today's Commentary

Corn futures ended the Wednesday session with most contracts 5 to 6 cents higher, following wheat. Wednesday’s weekly EIA report showed ethanol production for the week that ended 4/20 dropping 24,000 barrels per day to 985,000 bpd. That is the ...
Read More

Alan Brugler writes this daily agricultural markets overview with opening, midday and closing comments directed at the gain and meat Ag markets.

Add Data Columns to this Table
Learn about our Custom Views
Want to use this as
your default charts setting?
Learn about our Custom Templates
Switch the Market flag
above for targeted data.
Open the menu and switch the
Market flag for targeted data.
Get Streaming Chart Updates
Switch your Site Preferences
to Interactive Chart
New Chart Menu
Right-click anywhere on the chart to open the Interactive Chart menu.

Free Barchart Webinar